文献速递垂体与肾上腺疾病

泌乳素腺瘤:发病机制、诊断与管理

Prolactin-secreting adenomas: pathogenesis, diagnosis, and management.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-08-25

本综述评估泌乳素腺瘤的发病机制、诊断与管理证据。多巴胺激动剂(尤其卡麦角林)通常为一线治疗,每周最多2·0 mg用至少6个月可使多数患者泌乳素正常化、腺瘤缩小至少30%并恢复性腺功能。经蝶手术用于小腺瘤的一线治疗及多巴胺激动剂不耐受或抵抗者,放疗保留给难治性病例。

要点

  • 卡麦角林每周最多2·0 mg用至少6个月可使多数患者泌乳素正常化、腺瘤缩小≥30%并恢复性腺功能
  • 经蝶手术越来越多用于小泌乳素腺瘤的一线治疗,因缓解机会高
  • 多巴胺激动剂不耐受或抵抗者及难治性病例分别考虑经蝶手术和放疗

核心结论

  • 多巴胺激动剂尤其卡麦角林通常为泌乳素腺瘤的一线治疗,多学科管理和个体化方案是优化疗效的关键。

研究设计与样本

  • 本综述评估泌乳素腺瘤发病机制、诊断与管理的相关证据,并指出未来研究方向。

主要发现

  • 散发性泌乳素瘤是最常见的功能性垂体腺瘤,育龄期女性占优势,男性腺瘤通常更大且更具侵袭性。
  • 腺瘤以泌乳素、垂体特异性阳性转录因子1和雌激素受体α免疫染色阳性为特征。
  • 每周最多2·0 mg卡麦角林治疗至少6个月可使多数患者泌乳素浓度正常化、腺瘤缩小至少30%并恢复性腺功能。

关键数值与推荐

  • 卡麦角林每周最多2·0 mg用至少6个月,多数患者泌乳素正常化、腺瘤缩小至少30%、性腺功能恢复。
  • 经蝶手术用于小泌乳素腺瘤的一线治疗(缓解机会高)及多巴胺激动剂不耐受或抵抗者。
  • 放疗保留用于治疗难治性泌乳素腺瘤。

临床怎么用

  • 临床以多巴胺激动剂尤其卡麦角林作为多数泌乳素腺瘤的首选治疗。
  • 小泌乳素腺瘤可考虑经蝶手术作为一线治疗;多巴胺激动剂不耐受或抵抗者亦应转手术评估。
  • 难治性病例考虑放疗,并采用多学科管理与个体化方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperprolactinaemia can result from physiological causes, pharmacological agents, or pathological conditions such as prolactin-secreting pituitary adenomas and other pituitary stalk-compressing masses. Sporadic prolactinomas are the most common functioning pituitary adenomas, with a female predominance during reproductive years. In men, these adenomas are usually larger and more aggressive. Prolactinomas are characterised by positive immunostaining for prolactin, pituitary-specific positive transcription factor 1, and oestrogen receptor α. Dopamine agonists, particularly cabergoline, are typically used as primary therapy. Treatment with up to 2·0 mg per week of cabergoline for at least 6 months normalises prolactin concentrations, achieves adenoma shrinkage of at least 30%, and restores gonadal function in most patients. Transsphenoidal surgery is increasingly used as primary therapy for small prolactinomas given a high chance of remission; transsphenoidal surgery is also indicated for patients with dopamine agonist intolerance or resistance. Radiotherapy is reserved for treatment-refractory prolactinomas. Multidisciplinary management and an individualised approach are key to maximising therapeutic responsiveness and optimising outcomes. In this Review, we assess evidence relating to pathogenesis, diagnosis, and management of prolactinomas, and highlight opportunities for future research.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Fleseriu M, Varlamov EV, Akirov A, et al. Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2025. PMID: 40876473. doi:10.1016/S2213-8587(25)00227-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。